Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy
versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma
In this study, patients in the experimental arm will be treated by 4 PIPAC
(Cisplatine+Doxorubicine) alternating with 6 cycles of standard intravenous chemotherapy
(Cisplatine+Pemetrexed).
MESOTIP aim to show an improvement of the overall survival in the experimental arm.